Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS002 + Toripalimab in Advanced Cancer
NCT05128539Phase 1Terminated
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Feb 2022
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ongericimab in cancer, sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Adverse Events, Serious Adverse Events, Immune-related Adverse Events at 3 years, Dose-Limiting Toxicities at 3 years and 2 more. Started Feb 2022; status: terminated.
02
Drugs
ongericimab
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05128539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05128539.